Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe

Detalhes bibliográficos
Autor(a) principal: EuResist Network, INTEGRATE study group
Data de Publicação: 2022
Outros Autores: Abecasis, Ana, Gomes, Perpetua, Vandamme, A. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/143388
Resumo: Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association.
id RCAP_5a4b2979109e5fce4ff12f7d5cecc5d2
oai_identifier_str oai:run.unl.pt:10362/143388
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across EuropedolutegravireffectivenesselvitegravirHIVINSTIintegrase strand transfer inhibitorsraltegravirtreatment-experiencedHealth PolicyInfectious DiseasesPharmacology (medical)SDG 3 - Good Health and Well-beingFunding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association.Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects. Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012–2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated. Results: Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5–3.8] in IN-NV, 18.4% (95% CI: 15.8–21.2) in IN-V, 4.2% (95% CI: 3.6–4.9) in IE-NV and 23.9% (95% CI: 20.9–26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1–13.0) in IN-NV, 19.6% (95% CI: 17.5–21.6) in IN-V, 10.8% (95% CI: 10.0–11.6) in IE-NV and 21.7% (95% CI: 19.7–23.5) in IE-V subjects. Conclusions: Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.TB, HIV and opportunistic diseases and pathogens (THOP)Global Health and Tropical Medicine (GHTM)Instituto de Higiene e Medicina Tropical (IHMT)RUNEuResist Network, INTEGRATE study groupAbecasis, AnaGomes, PerpetuaVandamme, A. M.2022-08-30T22:38:15Z2022-082022-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article16application/pdfhttp://hdl.handle.net/10362/143388eng1464-2662PURE: 46201318https://doi.org/10.1111/hiv.13262info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:21:43Zoai:run.unl.pt:10362/143388Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:50:55.199062Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
title Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
spellingShingle Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
EuResist Network, INTEGRATE study group
dolutegravir
effectiveness
elvitegravir
HIV
INSTI
integrase strand transfer inhibitors
raltegravir
treatment-experienced
Health Policy
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
title_short Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
title_full Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
title_fullStr Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
title_full_unstemmed Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
title_sort Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
author EuResist Network, INTEGRATE study group
author_facet EuResist Network, INTEGRATE study group
Abecasis, Ana
Gomes, Perpetua
Vandamme, A. M.
author_role author
author2 Abecasis, Ana
Gomes, Perpetua
Vandamme, A. M.
author2_role author
author
author
dc.contributor.none.fl_str_mv TB, HIV and opportunistic diseases and pathogens (THOP)
Global Health and Tropical Medicine (GHTM)
Instituto de Higiene e Medicina Tropical (IHMT)
RUN
dc.contributor.author.fl_str_mv EuResist Network, INTEGRATE study group
Abecasis, Ana
Gomes, Perpetua
Vandamme, A. M.
dc.subject.por.fl_str_mv dolutegravir
effectiveness
elvitegravir
HIV
INSTI
integrase strand transfer inhibitors
raltegravir
treatment-experienced
Health Policy
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
topic dolutegravir
effectiveness
elvitegravir
HIV
INSTI
integrase strand transfer inhibitors
raltegravir
treatment-experienced
Health Policy
Infectious Diseases
Pharmacology (medical)
SDG 3 - Good Health and Well-being
description Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-30T22:38:15Z
2022-08
2022-08-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/143388
url http://hdl.handle.net/10362/143388
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1464-2662
PURE: 46201318
https://doi.org/10.1111/hiv.13262
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 16
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138104569757696